<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01708213</url>
  </required_header>
  <id_info>
    <org_study_id>CP 10664</org_study_id>
    <nct_id>NCT01708213</nct_id>
  </id_info>
  <brief_title>Safety Evaluation of Aline HA, an Implanted Cross-Linked HA Device</brief_title>
  <official_title>A Multi-center, Open-label, Prospective Study of Implanted Cross-linked HA Device, Aline HA, for Soft Tissue Augmentation, to Treat Only One Anatomic Feature in up to 100 Subjects for 6 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TauTona Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TauTona Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The protocol hypothesis is that treatment with Aline HA™ will be safe through 6 months as
      determined by clinical assessment of treatment sites and routine tracking of adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-center, open-label, prospective study of implanted cross-linked HA device, Aline HA,
      for soft tissue augmentation, to treat only one anatomic feature in up to 100 subjects for 6
      months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Treatment Site Responses Post Procedure</measure>
    <time_frame>6 months</time_frame>
    <description>The primary endpoint of this study is to assess treatment site responses and adverse events through 6 months post procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Decrease in the Wrinkle Severity Scale for Nasolabial Folds</measure>
    <time_frame>6 months</time_frame>
    <description>For this study, a decrease (at least one point) in the rating, relative to pre-treatment rating, when assessed by Investigators at the 1-Month, 3-Month, and 6-Month visits was considered clinically significant (P value less than 0.05).
WSS:
(0) - No wrinkle
- Just perceptible wrinkle
- Shallow wrinkle
- Moderately deep wrinkle
- Deep wrinkle, well-defined edges
- Very deep wrinkle, redundant fold</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Were Satisfied With the Treatment as Rated by GAIS</measure>
    <time_frame>6 months</time_frame>
    <description>This was measured using the Global Aesthetic Improvement Scale (GAIS). With the Global Aesthetic Improvement Scale (GAIS Scale) results of 1, 2 and 3 at 6 months were considered satisfied in this study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Disorder of Soft Tissue</condition>
  <arm_group>
    <arm_group_label>Dermal Filler - Aline HA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single armed study</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aline HA</intervention_name>
    <description>Implantable dermal filler</description>
    <arm_group_label>Dermal Filler - Aline HA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient must be ≥ 21 and ≤ 70 years of age.

          2. The patient must be willing and able to provide informed consent.

          3. The patient must be able to read.

          4. The patient is willing and able to comply with the study protocol.

          5. The patient is seeking soft tissue augmentation

          6. The patient has a pre-treatment Wrinkle Severity Score (WSS) ≥ 2 for any NLF to be
             treated.

          7. The patient agrees to follow-up examinations out to 6 months post final treatment.

        Exclusion Criteria:

          -  Exclusion Criteria: 1) The patient has had (or plans to have) cosmetic procedures to
             treat the intended treatment area, such as:

               1. Ablative or non-ablative resurfacing procedures including but not limited to
                  medium depth or deeper chemical peeling, dermabrasion, laser resurfacing or
                  fractional resurfacing that would affect the treatment area within the last 12
                  months.

               2. Laser or light based therapy that would affect the treatment area within the last
                  6 months.

               3. Face, neck or brow lift or other surgical procedure of the head and neck that
                  would affect the treatment area in the last 18 months.

               4. Non-permanent dermal filler treatment in the treatment area within the last 9
                  months.

               5. Permanent implant or dermal filler treatment in the treatment area at any point
                  in time.

               6. Neurotoxin treatment that would affect the treatment area in the last 6 months,
                  if the treatment area is below the eyes.

               7. Neurotoxin treatment that would affect the treatment area in the last 9 months,
                  if the treatment area is above the eyes.

                  2) The patient has had or plans to use a pharmaceutical (topical or oral)
                  anti-wrinkle product or other products (e.g., topical retinoids, hormone creams)
                  affecting inflammation in the treatment area within 30 days of the study 3) The
                  patient has inflammatory or infectious skin conditions or unhealed wounds in the
                  treatment areas.

                  4) The patient has a cancerous or pre-cancerous lesion and/or has had radiation
                  exposure in the treatment area in the last 24 months.

                  5) The patient has a history of anaphylaxis, multiple severe allergies, atopy, or
                  is allergic to lidocaine or amide-based anesthetics, hyaluronic acid products,
                  Streptococcal proteins or proteins from other gram positive organisms.

                  6) The patient has a history of significant bleeding disorders. 7) The patient
                  has scleroderma or fibrotic tissue disease. 8) The patient is female and of child
                  bearing potential and/or is pregnant or lactating or is not using medically
                  effective birth control, such as hormonal methods in use at least 30 days prior
                  to implantation, or barrier methods such as a condom and spermicide in use at
                  least 14 days prior to implantation.

                  9) The patient is using a Legally Authorized Representative. 10) The patient is
                  an employee or employee's family member of either the Study Sponsor or a Study
                  Site.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nowell Solish, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Nowell Solish</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5R3N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Westmount Institute of Plastic Surgery</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3Z1B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2012</study_first_submitted>
  <study_first_submitted_qc>October 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2012</study_first_posted>
  <results_first_submitted>September 3, 2014</results_first_submitted>
  <results_first_submitted_qc>December 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 17, 2014</results_first_posted>
  <last_update_submitted>December 16, 2014</last_update_submitted>
  <last_update_submitted_qc>December 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>soft tissue</keyword>
  <keyword>augmentation</keyword>
  <keyword>correction</keyword>
  <keyword>wrinkles</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dermal Filler - Aline HA</title>
          <description>Non-Randomized
Aline HA: Implantable dermal filler</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dermal Filler - Aline HA</title>
          <description>Single armed study
Aline HA: Implantable dermal filler</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.5" lower_limit="34" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Treatment Site Responses Post Procedure</title>
        <description>The primary endpoint of this study is to assess treatment site responses and adverse events through 6 months post procedure.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dermal Filler - Aline HA</title>
            <description>Non-Randomized
Aline HA: Implantable dermal filler</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Treatment Site Responses Post Procedure</title>
          <description>The primary endpoint of this study is to assess treatment site responses and adverse events through 6 months post procedure.</description>
          <units>percentage of participants with any AE</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Decrease in the Wrinkle Severity Scale for Nasolabial Folds</title>
        <description>For this study, a decrease (at least one point) in the rating, relative to pre-treatment rating, when assessed by Investigators at the 1-Month, 3-Month, and 6-Month visits was considered clinically significant (P value less than 0.05).
WSS:
(0) - No wrinkle
- Just perceptible wrinkle
- Shallow wrinkle
- Moderately deep wrinkle
- Deep wrinkle, well-defined edges
- Very deep wrinkle, redundant fold</description>
        <time_frame>6 months</time_frame>
        <population>Wrinkle Severity Score (WSS) assessment values of the Nasolabial Folds treatment area for the Per Protocol population (N=10) is a subgroup of the N=43 per protocol subjects treated. Reporting on the subjects with a 1 point improvement on the WSS at 6 months time.</population>
        <group_list>
          <group group_id="O1">
            <title>Dermal Filler - Aline HA</title>
            <description>Non-Randomized
Aline HA: Implantable dermal filler</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Decrease in the Wrinkle Severity Scale for Nasolabial Folds</title>
          <description>For this study, a decrease (at least one point) in the rating, relative to pre-treatment rating, when assessed by Investigators at the 1-Month, 3-Month, and 6-Month visits was considered clinically significant (P value less than 0.05).
WSS:
(0) - No wrinkle
- Just perceptible wrinkle
- Shallow wrinkle
- Moderately deep wrinkle
- Deep wrinkle, well-defined edges
- Very deep wrinkle, redundant fold</description>
          <population>Wrinkle Severity Score (WSS) assessment values of the Nasolabial Folds treatment area for the Per Protocol population (N=10) is a subgroup of the N=43 per protocol subjects treated. Reporting on the subjects with a 1 point improvement on the WSS at 6 months time.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Parametric testing</method>
            <param_type>Parametric Testing</param_type>
            <param_value>0.05</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Were Satisfied With the Treatment as Rated by GAIS</title>
        <description>This was measured using the Global Aesthetic Improvement Scale (GAIS). With the Global Aesthetic Improvement Scale (GAIS Scale) results of 1, 2 and 3 at 6 months were considered satisfied in this study.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dermal Filler - Aline HA</title>
            <description>Non-Randomized
Aline HA: Implantable dermal filler</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Were Satisfied With the Treatment as Rated by GAIS</title>
          <description>This was measured using the Global Aesthetic Improvement Scale (GAIS). With the Global Aesthetic Improvement Scale (GAIS Scale) results of 1, 2 and 3 at 6 months were considered satisfied in this study.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>As reported by the investigator or the subject</desc>
      <group_list>
        <group group_id="E1">
          <title>Dermal Filler - Aline HA</title>
          <description>To evaluate the safety and performance of Aline HA to treat mild to severe wrinkles in adult subjects</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Administration Site Conditions</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ann Thomas</name_or_title>
      <organization>TauTona Group</organization>
      <phone>650-331-2461</phone>
      <email>athomas@tautonagroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

